KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Revenue (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of Revenue data on record, last reported at $148.7 million in Q4 2025.

  • For Q4 2025, Revenue fell 23.63% year-over-year to $148.7 million; the TTM value through Dec 2025 reached $742.9 million, down 11.44%, while the annual FY2025 figure was $742.9 million, 28.81% down from the prior year.
  • Revenue reached $148.7 million in Q4 2025 per EBS's latest filing, down from $231.1 million in the prior quarter.
  • Across five years, Revenue topped out at $732.9 million in Q4 2021 and bottomed at $50.0 million in Q2 2024.
  • Average Revenue over 5 years is $277.1 million, with a median of $273.6 million recorded in 2023.
  • Peak YoY movement for Revenue: tumbled 85.2% in 2024, then skyrocketed 181.8% in 2025.
  • A 5-year view of Revenue shows it stood at $732.9 million in 2021, then tumbled by 54.95% to $330.2 million in 2022, then decreased by 16.23% to $276.6 million in 2023, then fell by 29.61% to $194.7 million in 2024, then dropped by 23.63% to $148.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $148.7 million in Q4 2025, $231.1 million in Q3 2025, and $140.9 million in Q2 2025.